The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy

[1]  D. Magliano,et al.  The burden and risks of emerging complications of diabetes mellitus , 2022, Nature Reviews Endocrinology.

[2]  D. Koya,et al.  Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches , 2021, Journal of clinical medicine.

[3]  D. Koya,et al.  Autophagy in metabolic disease and ageing , 2021, Nature Reviews Endocrinology.

[4]  M. Jardine,et al.  SGLT2 inhibitors may offer benefit beyond diabetes , 2020, Nature Reviews Nephrology.

[5]  K. Khunti.  SGLT2 inhibitors in people with and without T2DM , 2020, Nature Reviews Endocrinology.

[6]  M. Cowie,et al.  SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control , 2020, Nature Reviews Cardiology.

[7]  C. Bode,et al.  Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice , 2019, Scientific Reports.

[8]  K. Tsuchiya,et al.  Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice , 2019, Cardiovascular Diabetology.

[9]  H. Randeva,et al.  Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice , 2018, Cardiovascular Diabetology.

[10]  A. Murphy,et al.  SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice. , 2018, Atherosclerosis.

[11]  Sheng-Cai Lin,et al.  AMPK: Sensing Glucose as well as Cellular Energy Status. , 2017, Cell metabolism.

[12]  S. Kaneko,et al.  SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice , 2017, EBioMedicine.

[13]  Q. Pang,et al.  SIRT6 reduces macrophage foam cell formation by inducing autophagy and cholesterol efflux under ox‐LDL condition , 2017, The FEBS journal.

[14]  K. Park,et al.  The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE−/− mice fed a western diet , 2017, Diabetologia.

[15]  D. Hardie,et al.  The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels , 2016, Diabetes.

[16]  K. Guan,et al.  AMPK and autophagy in glucose/glycogen metabolism. , 2015, Molecular aspects of medicine.

[17]  T. Hirano,et al.  Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice , 2015, PloS one.

[18]  H. Koepsell,et al.  Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. , 2014, American journal of physiology. Renal physiology.

[19]  C. Monaco,et al.  Biomechanical factors and macrophages in plaque stability. , 2013, Cardiovascular research.

[20]  A. Galli,et al.  DNA Damage and Repair in Atherosclerosis: Current Insights and Future Perspectives , 2012, International journal of molecular sciences.

[21]  Jennifer Martinez,et al.  Macrophage autophagy plays a protective role in advanced atherosclerosis. , 2012, Cell metabolism.

[22]  D. Schrijvers,et al.  Drug-induced macrophage autophagy in atherosclerosis: for better or worse? , 2012, Basic Research in Cardiology.

[23]  Ira Tabas,et al.  Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. , 2011, Cell metabolism.

[24]  K. Moore,et al.  Macrophages in the Pathogenesis of Atherosclerosis , 2011, Cell.

[25]  P. Seglen,et al.  Does bafilomycin A1 block the fusion of autophagosomes with lysosomes? , 2008, Autophagy.

[26]  D. Klionsky,et al.  Autophagosome formation: core machinery and adaptations , 2007, Nature Cell Biology.